Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Express Scripts
Moodys
Merck
Boehringer Ingelheim

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Validus Pharms Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for VALIDUS PHARMS, and when can generic versions of VALIDUS PHARMS drugs launch?

VALIDUS PHARMS has six approved drugs.

There is one US patent protecting VALIDUS PHARMS drugs.

There is one patent family member on VALIDUS PHARMS drugs in one country.

Summary for Validus Pharms
International Patents:1
US Patents:1
Tradenames:4
Ingredients:4
NDAs:6

Drugs and US Patents for Validus Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Validus Pharms ROCALTROL calcitriol SOLUTION;ORAL 021068-001 Nov 20, 1998 AA RX Yes Yes   Start Trial   Start Trial
Validus Pharms BUMEX bumetanide TABLET;ORAL 018225-003 Jun 14, 1985 AB RX Yes No   Start Trial   Start Trial
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-001 Dec 10, 2004 RX Yes No 6,977,253   Start Trial   Start Trial
Validus Pharms ROCALTROL calcitriol CAPSULE;ORAL 018044-001 Approved Prior to Jan 1, 1982 AB RX Yes No   Start Trial   Start Trial
Validus Pharms BUMEX bumetanide TABLET;ORAL 018225-001 Feb 28, 1983 AB RX Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Validus Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-003 Dec 10, 2004 5,326,570   Start Trial
Validus Pharms BUMEX bumetanide TABLET;ORAL 018225-002 Feb 28, 1983 3,634,583   Start Trial
Validus Pharms BUMEX bumetanide INJECTABLE;INJECTION 018226-001 Feb 28, 1983 3,634,583   Start Trial
Validus Pharms ROCALTROL calcitriol CAPSULE;ORAL 018044-002 Approved Prior to Jan 1, 1982 4,341,774   Start Trial
Validus Pharms BUMEX bumetanide TABLET;ORAL 018225-001 Feb 28, 1983 3,634,583   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for VALIDUS PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 200 mg and 300 mg ➤ Subscribe 2007-08-21
➤ Subscribe Extended-release Capsules 100 mg ➤ Subscribe 2014-05-23
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Johnson and Johnson
Express Scripts
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.